Clarithromycin for the Treatment of Hypersomnia

Key facts

Sponsor

Lynn Marie Trotti

Principal Investigator

Lynn Marie Trotti, MD

Emory University

Intervention

Clarithromycin followed by placebo(drug)

Enrollment

26 enrolled

Eligibility

18 years · All sexes

Timeline

2010 – 2012

Study locations (1)

• Emory Sleep Center, Atlanta, Georgia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic hypersomnia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07500090
  A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
  Harmony Biosciences Management, Inc.
• RECRUITINGNCT06732284
  Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task
  Centre Hospitalier Universitaire de Nīmes
• RECRUITINGPHASE2NCT07096674
  A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
  Centessa Pharmaceuticals (UK) Limited
• RECRUITINGNANCT07006233
  A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
  University of Sydney
• RECRUITINGPHASE2NCT06843590
  A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
  Alkermes, Inc.
• RECRUITINGPHASE2NCT06812078
  A Study of TAK-360 in Adults With Idiopathic Hypersomnia
  Takeda
• RECRUITINGPHASE2, PHASE3NCT06767683
  A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
  Alkermes, Inc.
• RECRUITINGPHASE2NCT06752668
  A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
  Centessa Pharmaceuticals (UK) Limited

See all trials for Idiopathic hypersomnia →